OCEANSIDE, CA -- August 31, 2015 10:45 EST
Therapeutic Solutions International Acquires Preterm Labor and
Miscarriage Intellectual Property from OmniBiome Therapeutics
Inc
Company Seeks to Treat Pregnancy Complications by Probiotic
Based Immune Modulation
OCEANSIDE, CA--(Marketwire August 31, 2015) - Therapeutics
Solutions International (PINK:TSOI)
announced today the signing of an intellectual property purchase
agreement with OmniBiome Therapeutics Inc, in which proprietary
know-how related to modulating the immune system using
commercially-available probiotics to prevent complications of
pregnancy including pre-term labor and immunologically-mediated
miscarriages.
OmniBiome was founded in 2013 by David Palella, Alan Lewis, and
Thomas Ichim with the mission of being the world's first biotech
company focused on developing proprietary diagnostic, medical
device and therapeutic approaches to either utilize -- or intervene
with -- the systemic effects of the vaginal, lactal-duct and oral
microbiomes for improving maternal and fetal healthcare.
We are eager to continue the work of OmniBiome founder, the late
David Palella, who assembled a multi-disciplinary team of experts
to develop probiotic and microbiome technologies that address an
underserved but significant area of health care: maternal-fetal
medicine said Tim Dixon, President and CEO of Therapeutic Solutions
International. The current acquisition fits in closely with our
recently filed patent covering probiotic-based immune modulation
for prevention of recurrent spontaneous abortions, and is
complementary to the overall goal of the company, which is to
provide natural-based immune modulators for treatment of unmet
medical needs in niche markets.
Several studies have demonstrated that immune mediated
inflammation is a major cause of preterm labor and pregnancy
complications ([1], [2], [3]). Furthermore alterations in the microbiome
have been shown to elicit profound changes on the immune system
([4]), which according to the
intellectual property acquired, can be utilized therapeutically in
the context of pregnancy complications and preterm labor.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.